Holen Sie sich die Stockscreener-App
2.88
0.69%
-0.02
Schlusskurs vom Vortag:
$2.90
Offen:
$2.85
24-Stunden-Volumen:
268.31K
Relative Volume:
0.44
Marktkapitalisierung:
$43.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.4656
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
-8.57%
1M Leistung:
-49.83%
6M Leistung:
-52.48%
1J Leistung:
-83.39%
1-Tages-Spanne:
$2.81
$2.93
1-Wochen-Bereich:
$2.81
$3.25
52-Wochen-Spanne:
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.88 | 43.56M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - jammulinksnews.com
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - jammulinksnews.com
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - jammulinksnews.com
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - jammulinksnews.com
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - jammulinksnews.com
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - jammulinksnews.com
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - jammulinksnews.com
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - jammulinksnews.com
Why is Jasper Therapeutics Inc. Equity Warrant stock attracting strong analyst attentionMaximize portfolio value with smart investment plans - jammulinksnews.com
How does Jasper Therapeutics Inc. compare to its industry peersFree Stock Forecasts For 2025 - jammulinksnews.com
What institutional investors are buying Jasper Therapeutics Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
When is Jasper Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com
Does Jasper Therapeutics Inc. Equity Warrant stock perform well during market downturnsMassive wealth growth - jammulinksnews.com
How strong is Jasper Therapeutics Inc. Equity Warrant company’s balance sheetGain access to exclusive stock analysis - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant stock overvalued or undervaluedFree Stock Market Return Analysis - jammulinksnews.com
What is the dividend policy of Jasper Therapeutics Inc. stockMaximize gains with professional stock picks - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - WV News
Today is July 27 2025 - AInvest
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
When is the best time to buy Jasper Therapeutics Inc. Equity Warrant stockConsistently high yield - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockFree Stock Market Forecast Reports - Autocar Professional
What drives Jasper Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Is Jasper Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $29.75 Average Target Price from Analysts - Defense World
Jasper Therapeutics Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. stockMarket-beating performance - jammulinksnews.com
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jasper Therapeutics Inc-Aktie (JSPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):